Medicine
Therapeutic Drug Monitoring of Vancomycin for MRSA
Quick fact
Trough levels alone can lead to both undertreatment and nephrotoxicity.
Why this is interesting
You've probably heard of MRSA, the 'superbug' that resists many antibiotics. But did you know that the drug used to fight it, vancomycin, must be carefully monitored in the blood to work safely?
Read the full explanation
Understanding Therapeutic Drug Monitoring of Vancomycin for MRSA
Therapeutic drug monitoring (TDM) means measuring drug levels in a patient's blood to adjust the dose. For vancomycin, the goal is to keep the level high enough to kill MRSA but low enough to avoid harm, especially to the kidneys. Traditionally, clinicians measured the 'trough' – the lowest concentration just before the next dose – aiming for 15-20 mg/L for serious infections. However, research shows that the best predictor of effectiveness is the area under the curve (AUC) relative to the minimum inhibitory concentration (MIC) of the bacteria. That is, the total drug exposure over 24 hours compared to the concentration needed to inhibit the bug. This has shifted practice toward AUC-based monitoring, often using Bayesian software to estimate the AUC from one or two blood samples.
A deeper explanation
Vancomycin is a glycopeptide antibiotic that kills bacteria by binding to cell wall precursors, disrupting cell wall synthesis. Its efficacy is time-independent, meaning the key pharmacodynamic parameter is the ratio of the 24-hour AUC to the MIC (AUC/MIC). An AUC/MIC of 400-600 is associated with clinical success. TDM works because vancomycin's clearance varies widely among patients, especially with changing kidney function, so population dosing is unreliable. Monitoring troughs or AUC guides individualized dosing. The mechanism is that maintaining an adequate AUC ensures sustained exposure of MRSA to the drug, while avoiding excessive troughs (typically 20 mg/L) reduces the risk of acute kidney injury, likely due to oxidative stress and tubular damage. Thus, TDM translates pharmacokinetic variability into a safe, effective dose. Modern guidelines recommend AUC-based monitoring for serious MRSA infections, though troughs remain a practical surrogate in some settings.